• miR-196a Drives Esophageal Adenocarcinoma via MYC/TERT/NFκB

  2026-05-15

  This study reveals that microRNA-196a (miR-196a) promotes aggressiveness in esophageal adenocarcinoma (EAC) by activating the MYC/TERT/NFκB signaling axis, resulting in epithelial-to-mesenchymal transition and enhanced tumor progression. These insights identify c-Myc as a central node in the disease mechanism and suggest new molecular targets for cancer research.

• Temozolomide: Small-Molecule Alkylating Agent for Glioma Res

  2026-05-14

  Temozolomide stands as the benchmark small-molecule alkylating agent for dissecting DNA repair mechanisms and unraveling chemotherapy resistance, particularly in high-grade glioma models. This article delivers a data-driven, stepwise workflow, troubleshooting guide, and advanced use-case analysis—empowering researchers to maximize reproducibility and experimental insight with APExBIO's Temozolomide.

• Monomethyl Auristatin E: Precision Payload for Targeted Canc

  2026-05-14

  Monomethyl auristatin E (MMAE) empowers next-generation antibody-drug conjugates with unparalleled potency and selectivity, making it indispensable for research on tumor plasticity and therapy resistance. Discover optimized workflows, troubleshooting strategies, and cutting-edge applications that leverage MMAE’s unique properties for translational oncology.

• Bobcat339: Cytosine Structure-Based TET Enzyme Inhibitor in

  2026-05-13

  Bobcat339 empowers researchers to dissect DNA methylation dynamics with precision, offering a robust workflow for TET enzyme inhibition and gene transcription modulation. This guide translates recent multi-omics breakthroughs into actionable protocols, ensuring reproducible results in advanced epigenetics research.

• Dual-Action Inhibition of p38α MAPK: Mechanistic Advances an

  2026-05-13

  This study reveals how certain kinase inhibitors, including p38α MAPK inhibitors, promote dephosphorylation of the activation loop by stabilizing specific kinase conformations. These findings offer new avenues for designing inhibitors with dual-action properties to enhance specificity and potency in disease-relevant models.

• Moxidectin Potentiates Polyene Antifungals via Ergosterol Mo

  2026-05-12

  A 2024 study demonstrates that moxidectin, a macrocyclic lactone anthelmintic, increases ergosterol biosynthesis in Candida albicans, enabling synergistic inhibition of fungal growth alongside polyenes. This mechanistic insight suggests a promising approach to overcoming limitations in current antifungal therapy, with implications for translational research and drug repurposing.

• Agatoxin-IVA-Sensitive Calcium Channels in Cardiac Vagal Neu

  2026-05-12

  Wang et al. (2001) identified P-type (agatoxin-IVA-sensitive) calcium channels as critical mediators of both presynaptic and postsynaptic nicotinic activation in cardiac vagal neurons. This mechanistic insight advances our understanding of cardiac autonomic regulation and offers a refined approach to dissecting calcium-dependent neurotransmission in neurophysiology.

• Sodium phosphate dibasic (SKU B7293): Robust Buffering for R

  2026-05-11

  Discover how Sodium phosphate dibasic (SKU B7293) addresses real laboratory challenges in cell viability and aquatic toxicity assays. This article presents scenario-driven solutions for assay reproducibility, buffer compatibility, and vendor selection, empowering biomedical researchers to optimize workflows with evidence-backed recommendations.

• HotStart 2X Green qPCR Master Mix: Precision for Ferroptosis

  2026-05-11

  Uncover the advanced science behind HotStart 2X Green qPCR Master Mix for SYBR Green qPCR gene expression analysis, with a unique focus on ferroptosis and cell death pathways. This article explores technical advantages, rigorous protocol parameters, and critical insights from recent endometriosis research.

• CUDC-907: Technical Guidance for Dual PI3K and HDAC Inhibiti

  2026-05-10

  CUDC-907 addresses the need for simultaneous inhibition of PI3K/AKT and histone deacetylase pathways in cancer research models. It is best suited for in vitro cell-based assays requiring precise modulation of cell signaling, cell cycle, and apoptosis. This compound is not validated for diagnostic or clinical applications.

• Balsalazide’s Prodrug Strategy in Ulcerative Colitis Remissi

  2026-05-09

  This article reviews the mechanistic and clinical advances presented by Wiggins and Rajapakse (2009) regarding balsalazide, a novel 5-aminosalicylate prodrug, in the treatment of active ulcerative colitis. The study’s findings demonstrate enhanced efficacy and tolerability relative to established 5-ASA therapies, with implications for inflammation research and translational approaches to gastrointestinal mucosal protection.

• Sorafenib (BAY-43-9006): Protocols and Innovations in Cancer

  2026-05-08

  Sorafenib (BAY-43-9006) stands out as a versatile cancer biology research tool, enabling precise dissection of kinase-driven pathways and antiangiogenic mechanisms. This guide details enhanced workflows, troubleshooting strategies, and recent cross-domain insights, positioning Sorafenib from APExBIO as a core reagent for both tumor modeling and cutting-edge host-directed antiviral studies.

• EZH2-Mediated Autophagy Inhibition Drives Neuropathic Pain i

  2026-05-08

  Meng et al. demonstrate that elevated EZH2 in anterior cingulate cortex microglia aggravates neuropathic pain after brachial plexus avulsion (BPA) by inhibiting autophagy, implicating the MTOR pathway. Autophagy inhibition using 3-Methyladenine confirms the mechanistic link, providing new insight into neuroinflammation and pain maintenance.

• Acetylcholine Chloride: Frontiers in Cholinergic Signaling R

  2026-05-07

  Explore the advanced scientific applications of Acetylcholine Chloride in cholinergic neurotransmission research. This article provides a deep dive into its mechanism, assay optimization, and insights from recent gut-brain axis discoveries.

• XPO1 Inhibition by Eltanexor Modulates Wnt/β-catenin in CRC

  2026-05-07

  This study demonstrates that Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, effectively reduces colorectal cancer (CRC) tumorigenesis by modulating the Wnt/β-catenin signaling pathway and decreasing COX-2 expression. The findings highlight the chemopreventive potential of XPO1 inhibition in CRC and provide mechanistic insights for researchers developing targeted cancer therapeutics.

14584 records 1/973 page Next 12345 下5页 Last page